Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | JAK2 | O60674 | 5/20 | 0.56 |
| ▸ | JAK1 | P23458 | 4/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859622 | 0.78 | JAK2 (0.67) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL5422010 | 0.74 | POLB (0.79) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL25131975 | 0.73 | NPC1 (0.75) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL15764662 | 0.73 | NPC1 (1.00) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL15764656 | 0.73 | NPC1 (0.81) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL15764657 | 0.73 | JAK2 (1.00) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL27075082 | 0.72 | ROCK2 (0.46) | RAB9AJAK2S1PR1ROCK2ROCK1 | |
| SCHEMBL15764666 | 0.72 | NPC1 (0.81) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL7261149 | 0.70 | NPC1 (0.68) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL2928696 | 0.70 | NPC1 (0.51) | NPC1RAB9AJAK2JAK1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012081-B2 | Anthranyl amides and their use as medicaments | SCHERING AG (DE) | 2006-03-14 | — | — | US | disclosed |
| US-20050261343-A1 | Anthranilamides and their use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20040029880-A1 | Anthranyl amides and their use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1280762-A2 | ANTHRANYL AMIDES AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085671-A2 | ANTHRANYL AMIDES AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261343-A1 | Anthranilamides and their use as pharmaceutical agents | AADAC, ANTXR2, VEGFA | NPC1 3872/4885RAB9A 2554/4885JAK2 864/4885 |
| US-20040029880-A1 | Anthranyl amides and their use as medicaments | AADAC, ANTXR2, VEGFA | NPC1 3762/4885RAB9A 3402/4885JAK2 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.